Search clinical trials for: Filgotinib placebo

Total 53732 results

Novartis Pharmaceuticals

Completed

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (DIALOG)

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

United States, France, Korea, Republic of, Thailand, Italy, Netherlands, Turkey, Hungary, Russian Federation, Spain, United Kingdom, Japan, Malaysia
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Institut Bergonié
Novartis Pharmaceuticals

Withdrawn

Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer (ZAK-0)

Colon Cancer

France
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Completed

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Gastrointestinal Stromal Tumors

Germany, Italy
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (MACS0911)

Philadelphia Chromosome Positive | Chronic Myelogenous Leukemia in Chronic Phase

Japan
Fox Chase Cancer Center

Terminated

Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) (07060)

Gastrointestinal Stromal Tumors

United States
University of Michigan Rogel Cancer Center

Withdrawn

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Leukemia, Chronic Myeloid

United States
Novartis Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Netherlands, Italy, France, United Kingdom
Novartis Pharmaceuticals

Completed

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Germany, Canada, France, Spain, Italy
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (CoRNea)

Chronic Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Completed

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase ('MACS1252)

CML in Chronic Phase

Germany, Italy, Spain, Belgium, Croatia, Hungary, Netherlands, Austria, France, Greece, Sweden, Switzerland, Bulgaria, Romania, Slovenia, United Kingdom, Lithuania, Slovakia, Denmark, Finland, Norway, Poland, Czech Republic, Portugal, E... and more
Novartis Pharmaceuticals

Completed

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Chronic Myelogenous Leukemia

Poland
Novartis Pharmaceuticals

Completed

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

Gastrointestinal Stromal Tumors (GIST)

Israel
Atsushi Kawakami
Gilead Sciences

Recruiting

Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate (TRANSFORM)

Rheumatoid Arthritis | Biomarker | JAK Inhibitor | Musculoskeletal Ultrasound | IL-6 Inhibitor

Japan
Novartis Pharmaceuticals

Terminated

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations (MACS1148)

CML | Philadelphia Chromosome Positive (Ph+) | Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels

United States
Fox Chase Cancer Center
Novartis

Terminated

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Metastatic Disease | GIST

United States
Cancer Trials Ireland

Completed

Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States, Ireland, Israel, Germany
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Completed

Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults

Postmenopausal Osteoporosis

China
Novartis Pharmaceuticals

Completed

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation (ENESTgoal)

CML

United States
Novartis Pharmaceuticals

Terminated

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib (MACS0254)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Novartis Pharmaceuticals

Terminated

Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. (ENESTswift)

Philidelphia Positive Chronic Myeloid Leukaemia

Australia
Seoul St. Mary's Hospital
Novartis

Unknown

Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib (RE-NICE)

Chronic Myeloid Leukemia

Korea, Republic of
Lund University Hospital
Bayer

Withdrawn

Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost

Respiratory Distress Syndrome | Persistent Pulmonary Hypertension

Sweden
Insmed Incorporated

Completed

Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

Bronchiectasis

United States, United Kingdom, Bulgaria, India, Serbia, Ukraine, Greece, Hungary, Poland
University Health Network, Toronto
Novartis

Completed

Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia

Chronic Phase Chronic Myeloid Leukemia | Philadelphia Positive Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myeloid Leukemia | Blastic Phase Chronic Myeloid Leukemia | Resistant to Tyrosine Kinase Inhibitor Therapy

Canada
Broto, Javier Martín, M.D.

Unknown

Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum (GEIS-27)

Chondrosarcoma | Retroperitoneal Liposarcoma | Retroperitoneal Leiomyosarcoma

Spain
Novartis Pharmaceuticals

Active, not recruiting

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (ENESTop)

Chronic Myeloid Leukemia

Japan, Germany, Canada, Australia, France, Israel, Spain, United States, Greece, United Kingdom, Korea, Republic of, Brazil, Russian Federation, Argentina, Poland, Singapore, Belgium, Mexico
King Abdullah International Medical Research Center
Novartis

Terminated

Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy (NISRI)

Myeloid Leukemia, Chronic

Saudi Arabia
Novartis Pharmaceuticals

Completed

Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy Subjects

Healthy
Ulsan University Hospital
The Korean Society of Hematology CML working party

Unknown

Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML (NICE-BORA)

Untreated Adult Acute Myeloid Leukemia | Chronic Myeloid Leukemia in Myeloid Blast Crisis

Korea, Republic of
University Health Network, Toronto
Novartis Pharmaceuticals

Terminated

Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia

Acute Myeloid Leukemia

Canada
University of Jena

Completed

TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER)

Chronic Myeloid Leukemia

Germany, Switzerland, Czechia
Hyewon Chung

Completed

A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of Meformin

Healthy

Korea, Republic of
Cardeas Pharma

Completed

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia (IASIS)

Pneumonia, Bacterial

Spain, United States, Greece, Hungary, Turkey, Puerto Rico, France
Georgetown University
Novartis

Terminated

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Head and Neck Cancer | Colorectal Cancer

United States
National Cancer Institute (NCI)

Recruiting

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Neoplasms

United States
National Cancer Institute (NCI)

Recruiting

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Solid Tumors

United States
R.Bos
Leiden University Medical Center; Galapagos NV; Medical Centre Leeuwarden

Recruiting

Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH) (BACH)

Rheumatoid Arthritis

Netherlands
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase (CML0307)

Chronic Myeloid Leukemia

Italy
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Goethe University

Completed

Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia

Spain, Germany, France
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
Wuhan Union Hospital, China

Recruiting

Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

CML-CP; Mutation;Suboptimal Response or Failure in TKI

China
Technical University of Munich

Completed

Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Germany
The First Affiliated Hospital of Soochow University

Recruiting

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

CML, Chronic Phase; TKI

China
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States

Search clinical trials for: Filgotinib placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations